{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:52:11Z","timestamp":1786737131513,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijp.ijp_516_18","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T07:20:21Z","timestamp":1607152821000},"page":"372","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study"],"prefix":"10.4103","volume":"52","author":[{"given":"NisarAhmad","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShowkatAhmad","family":"Kadla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MohamadAmin","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BilalAhmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AsifIqbal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupakshi","family":"Pathania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufta","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.302505-1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","author":"Choo","year":"1989","journal-title":"Science"},{"key":"key-10.4103\/0253-7613.302505-2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence","author":"Mohd","year":"2013","journal-title":"Hepatology"},{"key":"key-10.4103\/0253-7613.302505-3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cld.2006.08.003","article-title":"The changing epidemiology and natural history of hepatitis C virus infection","author":"Bialek","year":"2006","journal-title":"Clin Liver Dis"},{"key":"key-10.4103\/0253-7613.302505-4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.1990.03450170079026","article-title":"Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection","author":"Alter","year":"1990","journal-title":"JAMA"},{"key":"key-10.4103\/0253-7613.302505-5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"key":"key-10.4103\/0253-7613.302505-6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","article-title":"Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C","author":"Poynard","year":"2001","journal-title":"J Hepatol"},{"key":"key-10.4103\/0253-7613.302505-7","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"key-10.4103\/0253-7613.302505-8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2008-1040787","article-title":"Serologic markers of hepatitis B virus infection","author":"Hoofnagle","year":"1986","journal-title":"Semin Liver Dis"},{"key":"key-10.4103\/0253-7613.302505-9","doi-asserted-by":"crossref","first-page":"99S","DOI":"10.1007\/BF02087883","article-title":"Treatment of chronic hepatitis C by interferon for longer duration than six months","author":"Poynard","year":"1996","journal-title":"Dig Dis Sci"},{"key":"key-10.4103\/0253-7613.302505-10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"key-10.4103\/0253-7613.302505-11","first-page":"245","article-title":"EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","author":"European","year":"2011","journal-title":"J Hepatol"},{"key":"key-10.4103\/0253-7613.302505-12","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon.A preliminary report","author":"Hoofnagle","year":"1986","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.302505-13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":", Perrillo RP, et al.Treatment of chronic hepatitis C with recombinant interferon alfa","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.302505-14","first-page":"1506","article-title":"Recombinant interferon alfa therapy for chronic hepatitis C.A randomized, double-blind, placebo-controlled trial","author":"Di","year":"1989","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.302505-15","unstructured":"American Association for the Study of Liver Diseases. Infectious Diseases Society of America Recommendations for Testing, Managing and Treating Hepatitis C Available at: Available from: http:\/\/hcvguidelinesorg\/full-report\/unique-patient-populations-patients-decompensated-cirrhosis. [Last accessed on 2016 Sep 01]."},{"key":"key-10.4103\/0253-7613.302505-16","doi-asserted-by":"crossref","unstructured":"Hauser G, Awad T, Brok J, Thorlund K, \u0160timac D, Mabrouk M, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev 2014;CD005441. doi.org\/10.1002\/14651858.CD005441.pub3.","DOI":"10.1002\/14651858.CD005441.pub3"},{"key":"key-10.4103\/0253-7613.302505-17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/MEG.0b013e328362dc22","article-title":"Therapy of chronic hepatitis C with PEG-IFN a-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses","author":"Fabris","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key-10.4103\/0253-7613.302505-18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/apc.2014.0247","article-title":"Treatment of hepatitis C in HIV-infected patients: Moving towards an era of all oral regimens","author":"Chen","year":"2015","journal-title":"AIDS Patient Care STDS"},{"key":"key-10.4103\/0253-7613.302505-19","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s10620-011-1770-3","article-title":"Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C","author":"Tohra","year":"2011","journal-title":"Dig Dis Sci"},{"key":"key-10.4103\/0253-7613.302505-20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-230X-10-21","article-title":"Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: The CLEO trial","author":"Mecenate","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"key-10.4103\/0253-7613.302505-21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1995-7645(14)60193-0","article-title":"Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective","author":"Waheed","year":"2015","journal-title":"Asian Pac J Trop Med","ISSN":"https:\/\/id.crossref.org\/issn\/1995-7645","issn-type":"print"},{"key":"key-10.4103\/0253-7613.302505-22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jmv.23592","article-title":"Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C","author":"Brochot","year":"2013","journal-title":"J Med Virol"},{"key":"key-10.4103\/0253-7613.302505-23","first-page":"392","article-title":"EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","author":"European","year":"2014","journal-title":"J Hepatol"},{"key":"key-10.4103\/0253-7613.302505-24","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.302505-25","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.302505-26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12072-012-9342-y","article-title":"APASL consensus statements and management algorithms for hepatitis C virus infection","author":"Omata","year":"2012","journal-title":"Hepatol Int"},{"key":"key-10.4103\/0253-7613.302505-27","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:50:35Z","timestamp":1786733435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_516_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"alternative-id":["302505"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_516_18","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}